In preclinical studies, AG-881 was shown to fully penetrate the blood-brain barrier and inhibit IDH1 and IDH2 mutations in cancer models. IDH1 and IDH2 are two metabolic enzymes
The Phase II trial is being conducted under an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and is the first to test
Oxycodone is used in the management of pain, especially in opioid tolerant patients. The company will introduce the product soon and will be amongst the few generic versions
Both the entities will jointly work to further develop the Etubics Platform, which is employed to develop new immunotherapeutic product candidates to treat cancer. As part of the
SMA is characterized by lower motor neuron loss and progressive muscle weakness and is caused by a genetic defect in the SMN1 gene that codes SMN, a protein
Progenics Pharmaceuticals has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Valeant. Relistor is a peripherally acting mu-opioid receptor antagonist designed to block
The trial is designed to evaluate the efficacy and safety of omadacycline compared with linezolid in ABSSSI. Omadacycline is the first in a new class of tetracyclines called
Selectins are a family of molecules, which are believed to play a major role in regulating cellular interactions within blood vessels. SCD is a rare and debilitating chronic
The new TCR candidates are directed against the HPV type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies to efficiently modify certain genes to improve T cell
The new intravenous antiplatelet agent adds to the company’s commercial offerings in the cardiac cath lab. The company intends to introduce kengreal, which is the first and only
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.